Alvotech - Ordinary Shares (ALVO)

Alvotech (ALVO) reflects a neutral-to-negative short-term sentiment backdrop, driven by a recent $165 million capital raise via public and private ordinary share offerings at $3.75, introducing equity dilution that pressures near-term trading despite funding biosimilar pipelines for major biologics like Humira and Stelara.